Reunion Neuroscience
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch REUN and buy or sell other stocks, ETFs, and their options commission-free!About REUN
Reunion Neuroscience, Inc. engages in operating the drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds.
CEOGregory T. Mayes, III
CEOGregory T. Mayes, III
Employees—
Employees—
HeadquartersToronto, Ontario
HeadquartersToronto, Ontario
Founded2020
Founded2020
Employees—
Employees—
REUN Key Statistics
Market cap13.12M
Market cap13.12M
Price-Earnings ratio-0.35
Price-Earnings ratio-0.35
Dividend yield—
Dividend yield—
Average volume30.83K
Average volume30.83K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$22.00
52 Week high$22.00
52 Week low$0.6303
52 Week low$0.6303
Stock Snapshot
As of today, Reunion Neuroscience(REUN) shares are valued at $1.12. The company's market cap stands at 13.12M, with a P/E ratio of -0.35.
Reunion Neuroscience(REUN) stock opened on 2025-12-05 at —. The price climbed to — and dipped to —.
Reunion Neuroscience(REUN) shares are trading with a volume of 0, against a daily average of 30.83K.
During the past year, Reunion Neuroscience(REUN) stock moved between $0.63 at its lowest and $22.00 at its peak.
During the past year, Reunion Neuroscience(REUN) stock moved between $0.63 at its lowest and $22.00 at its peak.
People also own
Based on the portfolios of people who own REUN. This list is generated using Robinhood data, and it’s not a recommendation.